ADAM17 and early-onset autosomal dominant Alzheimer disease: On the other hand, a study in the APP/PS1 mouse model of Alzheimer's disease demonstrated that overexpression of ADAM17 could influence cerebrovascular functions and cognitive abilities, highlighting its potential role in AD pathology and as a therapeutic target [105].